5-APDI (IAP)
5-APDI (5-(2-aminopropyl)-2,3-dihydro-1H-indene), also called IAP, is an aminoindane-related compound reported to act as a relatively balanced or serotonin-favouring monoamine releaser. It is largely uncharacterised in humans and circulated only briefly as a research chemical.
01 Overview
5-APDI is an indane-containing phenethylamine sometimes grouped with the aminoindanes and sometimes with the entactogens. Preclinical work suggests it releases serotonin, noradrenaline and dopamine, with a comparatively strong serotonergic component that gives it a more entactogenic character than 2-aminoindane.
Human data are effectively absent. It appeared in the research-chemical market as a novel entactogen-stimulant but never gained wide circulation, so almost everything here is inferred from limited in vitro studies and sparse anecdote.
02 Mechanism
Non-selective monoamine releaser at serotonin, noradrenaline and dopamine transporters, with a relatively prominent serotonergic component.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 20–60 mg | Insufflated | Unstudied; not recommended given serotonergic character. |
| Common | 40–100 mg | Oral | Anecdotal only; no validated dosing. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Entactogenic mood liftReported warmth and emotional openness. | Anecdotal | ||
| Mild stimulationGentle energy increase. | Anecdotal | ||
| Increased sociabilityTalkativeness and sociability. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin toxicity riskSerotonin release raises serotonin-syndrome risk with other serotonergic drugs. | Life-threatening | Unknown; risk with serotonergic combinations | Unconfirmed | |
| Cardiovascular strainRaised heart rate and blood pressure. | Severe | Common | Anecdotal | |
| Post-use low moodDepleted mood after use, typical of serotonergic releasers. | Moderate | Common | Anecdotal |